Karin Hessler is Vice President, IP Policy and Deputy General Counsel for the Association for Accessible Medicines (AAM). She provides legal advice to AAM staff and member company representatives on issues relating to generic and biosimilar medicines in the U.S. She works on advocacy strategy and engagement, provides advice on Hatch-Waxman and pharmaceutical patent issues and helps manage amicus briefs on behalf of AAM.
Before joining AAM in March 2019, Karin was a partner at Wiley Rein LLP, where she represented clients on intellectual property matters, with a special focus on patent litigation in the biotechnology and medical device industries. She has played a lead role in all phases of numerous Hatch-Waxman litigations, including expert discovery, fact discovery, claim construction, trials, regulatory analysis and settlement negotiations. Karin has significant experience in FDA regulatory issues as well as IPR process.
Karin received her J.D. from NYU School of Law, an M.A. in biochemistry from Duke and her B.S. in biochemistry from Lafayette College.